The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.
AstraZeneca is bolstering its cell therapy capabilities, agreeing on Monday to pay up to $1 billion for a biotechnology startup making treatments that reprogram cells inside the body.
The British drugmaker is buying EsoBiotech, a Belgian startup, for $425 million in cash upfront. EsoBiotech’s investors, among them Invivo Partners and UCB Ventures, could receive up to $575 million in additional payouts should the startup’s programs hit certain development and regulatory milestones, AstraZeneca said in a statement.
The deal hands AstraZeneca a technology designed to make cell therapies that can be administered through a single infusion, rather than via a complicated process that involves genetically manipulating cells in a lab. These so-called in vivo cell therapies, if successful, would help broaden the reach of traditional cell therapies, and be more convenient and accessible as well.
Several biotechs are pursuing in vivo cell therapy research, among them well-funded startups like Capstan Therapeutics and Umoja Biopharma. Some, such as Interius BioTherapeutics and EsoBiotech, have programs in early clinical testing. EsoBiotech in December started human testing of a multiple myeloma cell therapy called ESO-T01.That therapy, like others EsoBiotech is developing, uses what it calls novel, “highly targeted” lentiviruses to deliver genetic instructions into immune cells. This reprogramming process is done inside the body through an intravenous injection that takes “minutes” rather than the multiday or week turnaround typically associated with CAR-T therapy, AstraZeneca said.
Click here to continue reading.